Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Randomized Controlled trial. JAMA, 2011,305:2295–2303.
Siegel R, Ma J, Zou Z, et al. Cancer statistics 2014. CA Cancer J Clin, 2014,64:9–29.
International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr.
Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature, 2011,474:609–615.
Vaughan S, Coward JI, Bast RC, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev, 2011, 11:719–725.
Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol, 2004,164:1511–1518.
Devouassoux-Shisheboran M, Genestie C. Pathobiology of ovarian carcinomas. Chin J Cancer, 2015,34:50–55.
Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol, 2010,34:433–443.
Della Pepa C, Tonini G, Pisano C, et al. Ovarian cancer standard of care: are there real alternatives? Chin J Cancer, 2015,34:17–27.
Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res, 2013,19:961–968.
Bookman MA, Gilks CB, Kohn EC, et al. Better therapeutic trials in ovarian cancer. J Natl Cancer Inst, 2014,106:dju029.
Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol, 2014,15:852–861.
Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high grade ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol, 5s, 2014,32 suppl: abstr 5502.
Winterhoff BJN, Kommoss S, Oberg AL, et al. Bevacizumab may differentially improve survival for patients with the proliferative and mesenchymal molecular subtype of ovarian cancer. J Clin Oncol, 32:5s, 2014,32 suppl:abstr 5509.
Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer, 2015,34:4–16.
López-Guerrero JA, Romero I, Poveda A. Trabectedin as an emerging strategy in recurrent platinum-sensitive ovarian cancer treatment. Chin J Cancer, 2015,34:41–49.
Sun Y, Guo F, Bagnoli M, et al. The key nodes of a microRNA network associated with integrated mesenchymal subtype of highgrade serous ovarian cancer. Chin J Cancer, 2015,34:28–40.
Sigismondi C, Papaleo E, Viganò P, et al. Fertility preservation in female cancer patients: a single center experience. Chin J Cancer, 2015,34:56–60.